Regentis Biomaterials
Implantable Hydrogel Platform for Tissue Regeneration
Company Overview
Snapshot
Founded in September 2004 by Prof. Dror Seliktar, Regentis Biomaterials operates with 1–10 employees. The company has raised a total of $43.5 million across 4 funding rounds from 8 investors. In September 2025, Regentis Biomaterials became publicly listed on NASDAQ.
Business overview
Regentis Biomaterials is a Health Tech & Life Sciences company focused on tissue repair through its proprietary hydrogel platform. The company develops and commercializes degradable hydrogel implants, primarily for orthopedic treatments. Its flagship product, GelrinC, is a cell-free, off-the-shelf hydrogel implant designed to regenerate damaged articular knee cartilage. GelrinC is injected as a liquid, conforms to the lesion, and acts as a scaffold that gradually erodes as new cartilage forms, serving the medical devices and regenerative medicine sectors.
Strategic signal
Regentis Biomaterials is accelerating its commercialization efforts for GelrinC in Europe, evidenced by recent European regulatory approval for its new manufacturing process and plans to commence surgeon training. This indicates a strong push towards market entry and expansion, signaling to investors a significant step in realizing the commercial potential of its regenerative medicine technology.
Log in to access full profile ›Company Intelligence Q&A
- What is the primary focus of Regentis Biomaterials?
- Regentis Biomaterials focuses on developing and commercializing an implantable hydrogel platform for tissue regeneration, with current efforts concentrated on orthopedic treatments for damaged tissue.
- When did Regentis Biomaterials become a public company?
- Regentis Biomaterials became publicly listed on NASDAQ in September 2025.
- What is GelrinC and what is its purpose?
- GelrinC is Regentis Biomaterials' first commercial product, a cell-free, off-the-shelf hydrogel implant for treating painful injuries to articular knee cartilage. It acts as a scaffold for new cartilage growth.
- What recent regulatory approval did Regentis Biomaterials receive?
- In July 2026, Regentis Biomaterials received European regulatory approval for its new GelrinC manufacturing process, which increases production yield by 400%.
- What strategic moves is Regentis Biomaterials making in Europe?
- In June 2026, Regentis Biomaterials announced plans to commence European surgeon training for GelrinC, accelerating preparations for its commercial launch in the region.